These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 35764936)

  • 41. The impact of molecular profiling on cholangiocarcinoma clinical trials and experimental drugs.
    Sipra QUAR; Shroff R
    Expert Opin Investig Drugs; 2021 Apr; 30(4):281-284. PubMed ID: 33228417
    [No Abstract]   [Full Text] [Related]  

  • 42. Role of the fibroblast growth factor receptor axis in cholangiocarcinoma.
    Ang C
    J Gastroenterol Hepatol; 2015 Jul; 30(7):1116-22. PubMed ID: 25678238
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line.
    Yoon JH; Higuchi H; Werneburg NW; Kaufmann SH; Gores GJ
    Gastroenterology; 2002 Apr; 122(4):985-93. PubMed ID: 11910351
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Painful Eruptions in a Patient With Cholangiocarcinoma Treated With Fibroblast Growth Factor Receptor Inhibitor.
    Wylie NS; Sokumbi O; Starr JS
    JAMA Oncol; 2021 Dec; 7(12):1891-1892. PubMed ID: 34709371
    [No Abstract]   [Full Text] [Related]  

  • 45. Molecular perturbations in cholangiocarcinoma: Is it time for precision medicine?
    Braconi C; Roessler S; Kruk B; Lammert F; Krawczyk M; Andersen JB
    Liver Int; 2019 May; 39 Suppl 1():32-42. PubMed ID: 30829432
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses.
    Yoon JG; Kim MH; Jang M; Kim H; Hwang HK; Kang CM; Lee WJ; Kang B; Lee CK; Lee MG; Chung HC; Choi HJ; Park YN
    Hepatology; 2021 Oct; 74(4):1914-1931. PubMed ID: 33884649
    [TBL] [Abstract][Full Text] [Related]  

  • 47. S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma.
    El-Khoueiry AB; Rankin C; Siegel AB; Iqbal S; Gong IY; Micetich KC; Kayaleh OR; Lenz HJ; Blanke CD
    Br J Cancer; 2014 Feb; 110(4):882-7. PubMed ID: 24423918
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cholangiocarcinoma: shedding light on the most promising drugs in clinical development.
    Rahnemai-Azar AA; Pawlik TM
    Expert Opin Investig Drugs; 2021 Apr; 30(4):419-427. PubMed ID: 33645382
    [No Abstract]   [Full Text] [Related]  

  • 49. Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line.
    Park J; Tadlock L; Gores GJ; Patel T
    Hepatology; 1999 Nov; 30(5):1128-33. PubMed ID: 10534331
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Systemic therapy of cholangiocarcinoma: From chemotherapy to targeted therapies.
    Schweitzer N; Vogel A
    Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):345-53. PubMed ID: 25966433
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Unmet needs in the treatment of intrahepatic cholangiocarcinoma harboring
    Beri N
    Future Oncol; 2022 Apr; 18(11):1391-1402. PubMed ID: 35081733
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy.
    Sirica AE
    Hepatology; 2005 Jan; 41(1):5-15. PubMed ID: 15690474
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Gene and microRNA modulation upon trabectedin treatment in a human intrahepatic cholangiocarcinoma paired patient derived xenograft and cell line.
    Peraldo Neia C; Cavalloni G; Chiorino G; Ostano P; Aglietta M; Leone F
    Oncotarget; 2016 Dec; 7(52):86766-86780. PubMed ID: 27902465
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Induction of MKP-1 prevents the cytotoxic effects of PI3K inhibition in hilar cholangiocarcinoma cells.
    Leelawat K; Udomchaiprasertkul W; Narong S; Leelawat S
    J Cancer Res Clin Oncol; 2010 Oct; 136(10):1537-44. PubMed ID: 20145951
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Combining biological agents and chemotherapy in the treatment of cholangiocarcinoma.
    Jensen LH; Jakobsen A
    Expert Rev Anticancer Ther; 2011 Apr; 11(4):589-600. PubMed ID: 21504326
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma: current status, insight on resistance mechanisms and toxicity management.
    Chakrabarti S; Finnes HD; Mahipal A
    Expert Opin Drug Metab Toxicol; 2022 Jan; 18(1):85-98. PubMed ID: 35129006
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Systemic therapy for hepatocellular carcinoma and cholangiocarcinoma.
    Chung V
    Surg Oncol Clin N Am; 2015 Jan; 24(1):187-98. PubMed ID: 25444475
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Novel and emerging targets for cholangiocarcinoma progression: therapeutic implications.
    Kankeu Fonkoua LA; Serrano Uson Junior PL; Mody K; Mahipal A; Borad MJ; Roberts LR
    Expert Opin Ther Targets; 2022 Jan; 26(1):79-92. PubMed ID: 35034558
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma.
    Song F; Hu B; Cheng JW; Sun YF; Zhou KQ; Wang PX; Guo W; Zhou J; Fan J; Chen Z; Yang XR
    Cell Death Dis; 2020 Jul; 11(7):573. PubMed ID: 32709873
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Systemic treatment of advanced or recurrent biliary tract cancer.
    Zhang W; Zhou H; Wang Y; Zhang Z; Cao G; Song T; Zhang T; Li Q
    Biosci Trends; 2020 Nov; 14(5):328-341. PubMed ID: 32830166
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.